People with hemophilia who develop inhibitors cannot use standard clotting factor treatments and often rely on bypassing therapies such as recombinant activated factor VII (rFVIIa). This review examines how rFVIIa works to help blood clot and discusses differences between two approved versions of the therapy. While rFVIIa has been used successfully for more than 30 years, researchers continue to study its biological effects to better understand its safety, effectiveness, and role in future bleeding treatments.
Keywords:
blood platelets, endothelial protein C receptor, factor VIIa, hemophilia A, hemophilia B, hemostasis, tissue factor
